Atlantic Healthcare

About:

A rare disease pharmaceutical company acquiring, developing and commercializing therapeutics, specializing in gastroenterology.

Website: http://www.atlantichc.com/

Top Investors: Ionis Pharmaceuticals, LDC, The FSE Group, HM Treasury, Fullbrook Thorpe Investments

Description:

Atlantic Healthcare plc is a specialist pharmaceutical company, focused on developing and commercializing therapeutics that address unmet patient needs and rare diseases. Our work currently focuses on the gastrointestinal (GI) tract and targets the treatment of GI diseases, which have a debilitating effect on the lives of millions of people. We own the exclusive worldwide rights to alicaforsen, a pipeline within a drug, with the potential to establish a new class of treatments for Inflammatory Bowel Disease (IBD) and other GI diseases. We also own the worldwide rights to renzapride, a molecule with a unique dual mode of action and the potential to treat a variety of GI motility disorders.

Total Funding Amount:

$62.9M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Saffron Walden, Essex, United Kingdom

Founded Date:

2006-01-01

Founders:

Ronald Coffin, Toby Wilson Waterworth

Number of Employees:

11-50

Last Funding Date:

2019-06-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai